Compare F5 Inc (FFIV) vs 10X Genomics Inc (TXG) Price & Performance

F5 (FFIV) trades at $461.66, down 1.07% on the day, with a bullish technical outlook supported by moving averages and a strong fundamental backdrop. The company has consistently beaten earnings estimates, with Q2 2026 EPS of $4.73 surpassing the $4.00 consensus, and maintains robust profitability with a net income margin of 21.95%. Recent news highlights leadership in WAAP platforms and AI security partnerships, reinforcing growth prospects.

The stock offers upside potential driven by earnings momentum and strategic positioning in application security, though valuation multiples like a P/E of 36.78 suggest premium pricing. Key risks include competitive pressures and market volatility, while analyst consensus leans neutral with a $416.60 price target below the current price, indicating cautious optimism tempered by valuation concerns.

TXG trades at $77.28, up 1.55% on the day, showing resilience despite a bearish technical signal. The company's fundamentals are improving, with revenue reaching $642.82M in 2025 and net losses narrowing significantly to -$43.54M. Recent news highlights strong demand for its Atera spatial biology platform and a favorable patent verdict. However, valuation metrics like a P/S of 15.99 and EV/EBITDA of 249.22 remain elevated, reflecting high growth expectations.

The outlook is cautiously optimistic. The primary opportunity lies in the commercial success of new platforms like Atera and Sentira driving future profitability. Key risks include the high valuation requiring flawless execution, ongoing losses, and competitive pressures in the life sciences tools sector. Analyst sentiment is mixed, with a near-even split between Buy and Hold ratings and a consensus price target slightly below the current price.